STORM Therapeutics has dosed the first patient in a Phase 1b/2 combination study evaluating STC-15, a METTL3 inhibitor, with LOQTORZI (toripalimab) for multiple cancer types.
STC-15, a first-in-class METTL3 inhibitor, demonstrated clinical activity across various tumor types in a phase 1 study, with tumor regressions observed at all dose levels.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.